Liraglutide, a classic long-acting GLP-1 peptide API, is a well-established core pharmaceutical ingredient for antidiabetic and weight management formulations. Manufactured using a proprietary precision total-synthesis peptide process, the product achieves a purity of ≥99%. Trace impurities are strictly controlled in accordance with ICH and pharmacopeial quality standards, ensuring minimal batch-to-batch variation, excellent physicochemical stability, uniform biological activity, and consistently reliable product quality.
Produced under high-standard GMP-compliant cleanroom manufacturing facilities, the product is manufactured at stable kilogram-scale capacity and is supplied with a complete Certificate of Analysis (COA), comprehensive impurity profiling, and regulatory Drug Master File (DMF) documentation, fully supporting pharmaceutical R&D, pilot-scale production, commercial manufacturing, and regulatory submissions for injectable formulations. Featuring a proprietary fatty acid side-chain modification, liraglutide provides an extended half-life and sustained therapeutic activity. It delivers stable glycemic control, suppresses appetite, promotes weight and fat reduction, improves insulin sensitivity, and helps regulate blood lipid levels. It serves as a high-quality, compliant pharmaceutical intermediate for the development of generic and innovative therapeutics targeting diabetes mellitus and obesity.
This product is intended solely for use as a pharmaceutical intermediate and is not for direct human use.